Idiopathic Pulmonary Fibrosis therapeutic
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2020
Translate Bio Announces Second Quarter 2020 Financial Results and Reviews Recent Progress
(Streetinsider.com)
- "Translate Bio...today announced financial results for the second quarter ended June 30, 2020 and reviewed recent corporate achievements and updates....Anticipated Milestones: Preclinical pulmonary programs:...Idiopathic Pulmonary Fibrosis and Pulmonary Arterial Hypertension programs toward selection of development candidate."
Preclinical • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1